Floatz logo

Linaclotide

Opioid-Induced Constipation

Forest Laboratoriesprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Opioid-Induced Constipation cohort.

Asset / SponsorPhaseRating
Naldemedine
BioDelivery Sciences International
Phase 3BBB
Methylnaltrexone
Bausch Health Americas, Inc.
Phase 3B
Prucalopride
Shire
Phase 3B
Lactobacillus Gasseri Bgp345A
BioGaia Pharma AB
Phase 2B
MORPHINAN-3,6,14-TRIOL, 4,5-EPOXY-17-(2-PROPENYL)-, (5.ALPHA.,6.BETA.)-
S.L.A. Pharma AG
Phase 2B

View all 10 →

Same molecule, other indications

Linaclotide is also rated in:

colorectal adenomaDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →
Healthy, no Evidence of DiseaseDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →